Corporate Governance

Strategy:

Microsaic’s strategic aim is to capitalise on its strengths in point of need MS detection, and access high-growth and emerging life science applications. The Company intends to achieve its strategy with a business model built on customer focus and technology innovation.

Business Model:

Microsaic’s core strengths are its technical and product development capabilities and its experience in working with OEM partners to co-develop integrated separation and detection systems.

The Company derives revenues from the sale of products, sale of consumables and spare parts, and service and support income.

The Company’s commercial approach is highly flexible to suit each partner’s needs, helping to craft the OEM’s application in the early stages of scientific proof of principle, or into a broader product concept. Microsaic has proven expertise in technology development and commercialisation. Microsaic also brings expertise from its leading scientists, technologists, and engineers to meet the OEM’s near term or longer-term challenges.

Building partnerships over the long-term will establish greater competitive advantage for the Company, as its products are tailored to specific application needs.

Challenges:

Staying relevant with future customer needs
Customer needs evolve rapidly. Future product specifications will be driven by end-user requirements. This will inform Microsaic’s product strategy as its MS Detectors move from the laboratory into production, and front-line operating environments. Microsaic will ensure that its strategic product development will remain focused on meeting demanding bioprocessing applications.

Remaining innovative in an advancing technological landscape
Microsaic has successfully developed and implemented advanced technology at the core of its design with over 60 patents to date. This has led to a solid foundation serving scientists in the laboratory in small molecule drug discovery.

The Company continues to invest in several product development projects with its core MiD® MS Detector platform, which the Board believes will be attractive to the growing market for laboratory-based applications with larger biological molecules, such as peptides and small proteins.

In the longer-term, the Company will extend its product capabilities further into life science applications, such as bioprocessing, where a range of biological entities, including monoclonal antibodies, can be analysed by direct analysis in minutes. This compares with traditional analysis in remote centralised laboratories sometimes taking many days or even weeks to deliver results.

The Company’s aim is to maintain and enhance good relations with its shareholders. The Company’s interim and annual reports are supplemented by capital market presentations to analysts and shareholder groups. The Company is available to meet with shareholders outside these times if required. The Company keeps shareholders up to date with the latest developments through its website and regulatory news service announcements on technological, commercial and financial progress.

The Chief Executive Officer and the Financial Director are primarily responsible for maintaining dialogue with shareholders, supported by the Company’s broker and financial PR advisers. The Chief Executive Officer and Finance Director hold one-to-one and sometimes group meetings with key shareholders and analysts following the announcement of the annual and interim results. The Chairman will also attend a number of these group meetings. Following these meetings, the Company’s brokers provide independent feedback to the Board on shareholders’ views and concerns. The Company’s financial PR adviser also provides anonymised feedback to the Board on the views of analysts who have met the Company.

The AGM is the principal forum for dialogue with private shareholders, and we encourage all shareholders to attend and participate. The Chairman, Chief Executive Officer and Finance Director, together with all other directors whenever possible, attend the AGM and are available to answer questions raised by shareholders. Unfortunately, very few private shareholders attend the AGM which is a problem for AIM companies generally.  The Finance Director contacts larger shareholders before general meetings to ensure they have submitted their proxy voting forms, and this also provides an opportunity to hear any concerns.

Where feedback is received directly from shareholders or shareholder advisory groups, for example relating to voting intentions on general meeting motions, this is brought to the attention of and discussed by the Board.

Contact Details:

Glenn Tracey
Chief Executive Officer
[email protected]
tel: (0) 1483 751 577

Bevan Metcalf
Finance Director
[email protected]
tel:(0) 1483 751 577

Stakeholder: Staff

Our ability to implement the long-term strategy is heavily dependent on hiring and retaining specialist technical and commercial staff.

Reason for engagement:

High quality communications with staff is a key requirement for high levels of engagement, fostering a culture of innovation.

How we engage:

• Quarterly staff briefings where there is a two-way dialogue where staff are updated on the progress of the business and can ask questions about the progress of the business and the longer term strategy.
• Share options are granted to all staff, which link shareholder goals to longer term company performance.
• The Company is mindful of the importance of work-life balance for employees and their families and within the constraints of a small organisation offers flexible working hours and home working where-ever possible.
• Where-ever possible the Company offers training and career development opportunities which are very important in retaining staff.
• The Company provides a supportive work environment where dialogue is open and honest and where all staff are treated equally.
• Science is a creative discipline, and diversity of thought fundamentally underpins successful outcomes. The Company has an active Diversity and Inclusion program, initiated, promoted, and supported by the Chief Executive Officer directly.

Stakeholder: Clients

Our success and competitive advantage are dependent upon fulfilling client requirements, both in the short term (shipping product), and in the longer-term (customised R&D specific to that customer).

Reason for engagement:

Understanding current and emerging requirements of clients enables the Company to develop new and enhanced product specification and application areas.

How we engage:

• We specifically seek customer requirements during business development meetings with new and existing clients.
• Obtain fulfilment metrics employed by clients to measure on-going performance.
• Provide robust and reliable products which meet our rigorous quality standards. The Company is ISO 9001 2015 compliant.
• Ensure warranty terms on units are in line with industry standards.

This has led to an increase in new business development opportunities, bringing to market products that customers have specifically asked for, and on-going improvements in our products and service.

Stakeholder: Suppliers

Outsourced fabrication is identified as a key stakeholder.

Reason for engagement:

We outsource our manufacturing and assembly to a specialist high-technology fabrication facility in the UK.

How we engage:

• We have documented all assembly and sub-assembly processes, with a view to simplifying outsource and removing subjective communications.
• We co-invest in supplier set-up and infrastructure.
• We invest in regular supplier training.
• We operate systems to ensure supplier quality, which are discussed on a regular basis.
• We pay our suppliers in accordance with their terms and do not delay payments.

This has resulted in a long-term relationship, founded on a large body of data, metrics and mutual trust.

Stakeholder: Shareholders

As a public company we provide transparent, easy-to-understand and balanced information to ensure support and confidence.

Reason for engagement:

Meeting regulatory requirements and understanding shareholder sentiments on the business, its prospects and performance of management.

How we engage:

• Regulatory news releases. With effect from 3 July 2016 and in accordance with the Market Abuse Regulation, where regulatory announcements include inside information this is indicated in the announcement itself.
• Keeping the investor relations section of the website up to date.
• Annual and half-year reports and presentations provided to analysts and key shareholders.
• The AGM gives shareholders the ability to ask questions of the Board.
• Capital market events.
• We believe we successfully engage with our shareholders.

Stakeholder: Industry bodies

The services we provide must meet certain requirements.

Reason for engagement:

The membership of certain industry groups, including certain regulatory standards (e.g. CE marking, ISO) are influential in the way the group is perceived by new and existing clients.

How we engage:

• Ongoing product certification is central to our product development.

Stakeholder: Environment

As a company dealing with a complex range of raw and processed materials, we must ensure that our business is conducted sustainably.

Reason for engagement:

Whilst not of substantial impact compared with many other manufacturing businesses, the Company recognises its activities have an impact on the environment and acknowledges its responsibility to ensure this is minimised.

How we engage:

• In accordance with the requirements of the Waste Electrical and Electronic Equipment Regulations (WEEE), the Company is registered with the UK Environment Agency as a Small WEEE Producer and disposes of electrical equipment waste responsibly.
• The Company reviews the substances it uses within its design and manufacturing processes with the aim of using environmentally friendly products commensurate with producing high quality products and the RoHS directive (Restriction of the use of certain hazardous substances).
• Where possible, products are recycled within the Company.
• Paper, cardboard, batteries and printer cartridge recycling collection facilities are in place and are regularly used in the Company’s offices.
• Redundant computer equipment is disposed of in accordance with good practice.

Stakeholder: Health and Safety

As a Company we believe our employees have the right to come home safe and well from their job.

Reason for engagement:

It is our mission to prevent work related accidents and ill health.

How we engage:

• Assessing the risk to the health and safety of employees and others who may be affected and identifying what measures are needed to comply with its health and safety obligations.
• Providing and maintaining locations, equipment, protective clothing and systems of work that are safe and without risks to health.
• Ensuring that all necessary safety devices are installed and maintained on equipment.
• Providing information, instruction, training and supervision in safe working methods and procedures.
• Promoting the co-operation of employees to ensure safe and healthy conditions.
• Establishing a safety committee, safety representatives and accident investigations where applicable.
• Establishing emergency procedures as required.
• Monitoring and reviewing the management of health and safety at work.

The Board aims to ensure that the Company’s risk management framework identifies and addresses all relevant risks in order to execute and deliver the strategy.

The Directors recognise their responsibility for the Company’s system of internal control and have established systems to ensure that an appropriate and reasonable level of oversight and control is provided.  The Company’s systems of internal control are designed to help the Company meet its business objectives by appropriately managing, rather than eliminating, the risks to those objectives. The controls can only provide reasonable, not absolute, assurance against material misstatement or loss.

The Company’s Management Team, who report into the Executive, meets with the Executive at least quarterly to review commercial, operational and financial risks facing the business. These risks are assessed according to their nature and magnitude and given a score based on the seriousness of the risk and the likelihood of the risk occurring. The effectiveness of the controls implemented to minimise the risks are also reviewed. The aim of these reviews is to provide reasonable assurance that material risks are identified and appropriate action is taken at an early stage. From this review the Company maintains its internal risk register which on an annual basis is reviewed and updated by the Finance & Audit Committee and the Board.  New material risks which arise in the meantime, such as the potential effect of Brexit, are added to the risk register and discussed at Board level as they arise.

The Company has also implemented a system called PACE (Product and Cycle Time Excellence) as a key part of its evaluation and monitoring of R&D projects. PACE identifies the risks facing each of the Company’s projects and how to mitigate each risk.

The annual budget is reviewed and approved by the Board. Financial results, with comparisons to budget and latest forecasts are reported on a monthly basis to the Board together with a report on operational achievements, objectives and issues encountered. Significant variances from plan are discussed at Board meetings and actions set in place to address them.

Measures continue to be taken to review and improve internal controls and risk management procedures. The Company implemented a Financial Procedures Manual including approval levels for authorisation of expenditure, potential fraud scenarios, payment approval process, expenses guidelines etc. This is updated and approved by the Board on an annual basis.

The Company’s auditors are encouraged to raise comments on internal control in their management letter following the annual audit. The points raised and actions arising are monitored through to completion by the Finance & Audit Committee.

PRINCIPLES TO MAINTAIN A DYNAMIC MANAGEMENT FRAMEWORK

The Board currently consists of two Executive Directors and three Non-Executive Directors. In 2019 the Board of Directors held 12 meetings including 9 face to face and 3 by conference call.

The Company has an equal opportunity policy to recruitment at Board level and within the Company at large and seeks diversity as opportunities arise, within the framework of selecting the most suitable person, based on relevant skills, abilities, experience and location, as required for the role.

The principal role of the Chairman of the Board is to manage and to provide leadership to the Board of Directors of the Company.  The Chairman is accountable to the Board and acts as a direct liaison between the Board and the management of the Company, through the Chief Executive Officer.  The Chairman acts as the communicator for Board decisions where appropriate.

The Chairman is independent from management and free from any business or other relationship which could interfere with his independent judgment

The Chairman is responsible for the effective leadership, operation and governance of the Board and its Committees. He ensures that all Directors contribute effectively to the development and implementation of the Company’s strategy, while ensuring that the nature and extent of the significant risks the Company is willing to embrace in the implementation of its strategy are determined and challenged.

The Chief Executive Officer is responsible for the management of the Company, providing executive leadership and for implementing the Company’s strategy.

The Chairman was considered independent upon his appointment in January 2018. The Board believes that the advice, behaviour and character of its other Non-Executive Directors (Messrs Yeatman and Buckley) is independent and at all times in the best interests of the Company and all its shareholders. In addition, the skills and business judgement which they possess and regularly exercise contributes to the efficient and effective running of the Company. The Company’s Senior Independent Director, is Mr Eric Yeatman.

The Company appreciates that circumstances which might, or might appear, to affect a director’s judgement may well include financial dependence on the Company and whether the Director is, or represents, a major shareholder. None of the Non-Executive Directors or Non-Executive Chairman are financially dependent on the Company as they all have other jobs in either industry or academia. In addition, none of the Non-Executive Directors has a significant shareholding defined as greater than 3% in the Company, or represents a significant shareholder.

Under the QCA Guidelines the independence of the Chairman and Non-Executive Directors could be challenged under the following areas, but in all cases the Board believes that all the Non-Executive Directors act in an independent manner at all times:

Name and position	Potential issue	Why independence not compromised
Peter Grant Non-Executive Chairman	Holds 3.5M share options in the Company. This was a one-off award when Mr Grant joined the Company in January 2018 and is subject to objective performance conditions which are aligned with Executive Directors. Chairs the Finance & Audit Committee	This was a one-off award granted, following consultation with a major shareholder, and required to attract a Chairman of the appropriate calibre to the Company. The performance conditions are objective, based on tangible progress by the Company, and the vesting of options will be managed by the Non-Executive Directors without input from the Chairman as regards his options. Peter is Chair of the Finance & Audit Committee in view of his qualification as a Chartered Accountant (FCA) and relevant experience as a Finance Director and as Audit Committee Chairman on various listed companies.
Chris Buckley Non-Executive Director	Briefly held the position of VP Marketing prior to becoming a Non-Executive Director. Holds 75k options in the Company. These were awarded prior to Mr Buckley taking up his role as Non-Executive Director.	Chris’s short tenure as VP Marketing has not compromised his effective independence as a Non-Executive Director. The number and potential value of options is relatively small in relation to Chris’ full time earnings, and were awarded in the context of work prior to being a Non-Executive Director.
Eric Yeatman Non-Executive Director	Has previously held the position of Chief Executive Officer on an interim basis. As a founder, has been on the Board for over 9 years	Eric stepped into the role of Chief Executive Officer on an interim basis when a vacancy arose; but notwithstanding this, at all times acts as an independent Non-Executive Director. As a Professor at Imperial College, London, Eric brings technical knowledge to the Board which is useful for a small business.

The Board has an established Finance & Audit Committee, and Remuneration Committee. The Company believes it is currently too small to have a separate Nominations Committee, so this role is taken on by the Board of Directors as a whole.

Details and links to the terms of reference of the Finance & Audit Committee and Remuneration Committee are set out under Principle 9 below.

Details of Directors and their time commitment is set out under Principle 6 below.

The number of Board and committee meetings and attendance records of directors is set out in the Annual Report and Accounts and under Principle 9 below.

Peter Grant, Independent Chairman

Term of office: Appointed Non-Executive Chairman on 1 January 2018. Peter’s most recent re-election as Director was on 4 May 2018 at the Company’s AGM, when he retired per Article 81.1 (a) of the Articles of Association.

Peter chairs the Finance & Audit Committee and is a member of the Remuneration Committee of the Company.

Background and suitability for the role: Peter Grant had an executive career spanning 40 years, nearly half at listed company board level spanning the healthcare, electronics, software and engineering industries. His executive career included CEO of Skyepharma PLC, CFO of Skyepharma PLC, Group Finance Director at Eurodis Electron PLC, CFO at WorldPay Group plc, Group Chief Executive at Molins PLC and Finance Director at Molins PLC. Prior to this he held a variety of senior commercial, financial and general management roles in the General Electric Company PLC group of companies. He holds an MA in Mathematics from the University of Oxford and is a Chartered Accountant. He brings a combination of listed company and financial expertise, experience of developing, manufacturing and distributing electronic and software products and experience of the healthcare sector.

Current external appointments: Peter is Chairman and Chair of the Audit and Nomination Committees and member of the Remuneration Committee of LiDCO Group plc, and a Non-Executive Director of Labatec Pharma SA, a private Swiss company.

Peter estimates that his current appointments, including that with the Company, comprise about 8 days a month, and he considers that he would have the time to be able to step up the commitment to the Company should temporary circumstances require him to do so.  Peter keeps his skills up to date by regularly reading various publications on changes in regulations and the business environment affecting companies, especially in the healthcare sector.

Glenn Tracey, Chief Executive Officer

Term of office: Joined March 2015 as Chief Operating Officer. Appointed to the Board December 2015, and appointed as Chief Executive Officer in September 2017. Glenn’s most recent re-election as Director was on 14 May 2019 at the Company’s AGM, when he retired per Article 81.1 (b) of the Articles of Association.

Background and suitability for the role: Glenn has more than 20 years’ experience leading operations, marketing and high technology collaboration, and research and development for small and large companies in sensing and detection instrumentation, across applications in human and environmental health. Glenn specialises in scaling new technology into emerging markets, especially transitioning contemporary high-end detection laboratory technologies to point of need or field-based sensing across a number of markets such as food, air, water and pharmaceuticals.

Glenn holds a BSc in Applied Chemistry from Salford University, and an MBA from the Open University.

Glenn has no external appointments.

Bevan Metcalf, Part-time Finance Director and Company Secretary

Term of office: Appointed to the role of Part-time Finance Director on 18 December 2015 and Company Secretary on 16 May 2019. Bevan Metcalf is employed for 13 days per month. Any additional days are paid on an agreed day rate on a quarterly basis. Bevan Metcalf has the flexibility to increase his time during busy periods as Microsaic is his only role. Bevan’s most recent re-appointment as a Director of the Company was on 4 May 2018, at the Company’s AGM, when he retired per Article 81.1 (c) of the Articles of Association.

Background and suitability for the role: Bevan has a Business Management Degree from the University of Waikato, Hamilton, New Zealand where he majored in Accounting. He is also an ACA Member of the Chartered Accountants of Australia and New Zealand.

Bevan has 40 years’ of financial management experience with international companies primarily in the mining and pharmaceuticals sectors, including Beowulf Mining, Afferro Mining, African Eagle Resources, Orion Corporation, GlaxoSmithKline, Charles Parsons Ltd and ICI. In the past 14 years he has been involved with companies listed on the AIM market of the London Stock Exchange and on the Toronto Stock Exchange as Finance Director, Company Secretary, Chief Financial Officer and in a Non-Executive Director capacity. He therefore understands the Governance and MAR regulations impacting the Company.

Bevan’s 20 years’ experience in the Pharmaceutical Industry is very relevant to the strategy of the Company which is targeting the pharmaceutical industry for its miniaturised mass spectrometers.

Bevan keeps his accounting skills up to date through his membership of the Chartered Accountants of Australia and New Zealand where he accesses their library of resources and receives journals and other reading materials on a regular basis.

Bevan has no external appointments.

Professor Eric Yeatman, Non-Executive Director

Term of office: Director since the foundation of the Company in 2001. Non-Executive Director during this period except:

• Chairman: 2004 – December 2011
• Interim Chief Executive Officer: December 2011 – November 2012
• Chairman: November 2012 – June 2013
• Interim Chairman: February 2017 – December 2017

Eric is also Chairman of the Remuneration Committee since 1 January 2018, and has previously chaired the Finance & Audit Committee. His most recent re-election as Director was on 14 May 2019, at the Company’s AGM, when he retired per Article 81.1 (b) of the Articles of Association.

Background and suitability for the role: Eric Yeatman has been an active researcher in micro-technology, on which the Company’s unique products are based, since 1986. He obtained his PhD in 1989 and has since been a member of academic staff of Imperial College London, one of the world’s top 20 universities, becoming full Professor in 2005. He has published over 200 papers in related fields, with over 8000 citations, and is inventor or co-inventor on 10 patents. As a co-founder, he is intimately familiar with the evolution of the Company and its technology. He has served on the advisory boards of two venture capital funds and one high technology company. He is a Fellow of the Royal Academy of Engineering, and was awarded its Silver Medal in 2011, given “to recognise an outstanding and demonstrated personal contribution to British engineering”.

Current external appointments: Prof. Yeatman is Head of the Department of Electrical and Electronic Engineering of Imperial College London. Prof. Yeatman is also an NED of Imperial Consultants. He is a member of the Enterprise Committee of the Royal Academy of Engineering. He serves on a number of advisory committees and boards of international technical conferences and journals. These other commitments do not prevent him spending whatever time is needed to fully exercise his duties and responsibilities as a Non-Executive Director of the Company, and none creates a conflict of interest with, or imposes a relevant restriction on, his duties to the Company.

Chris Buckley, Non-Executive Director

Term of office: Appointed Director appointed in April 2016. Chris Buckley is also a member of the Finance & Audit committee and the Remuneration Committee. Chris’ most recent re-election as Director was on 14 May 2019, at the Company’s AGM, when he retired per Article 81.1 (b) of the Articles of Association.

Background and suitability for the role: Chris Buckley has 35 years of experience in the global healthcare industry, spanning international marketing and general management assignments. He has a proven track record of translating scientific innovations into competitive customer-focussed benefits. Chris holds a degree in pharmacology and biology from the University of Aston, UK.

Chris spent 27 years of his career with Novartis, predominantly in the Consumer Healthcare and Pharma divisions, where he progressed through a variety of local, regional and global roles. He brings to Microsaic, a wealth of strategic management experience, coupled with the pragmatic and commercial expertise to effectively grow brands.

Current external appointments: Chris has no external appointments

Chris’s experience in the pharmaceutical and in-vitro diagnostics Industries is very relevant to Microsaic’s strategy, since the Company is targeting the pharmaceutical industry for its miniaturised mass spectrometers.

A Fellow of the Chartered Institute of Marketing (FCIM), where he has access to a marketing resource library and marketing training programmes.

The Company from time to time uses external advisers.

During 2019, The Board has retained the following advisers:

• PhilipHare and Associates for advice on the handling of Venture Capital Trusts (VCT) and Enterprise Investment Schemes (EIS)
• N+1 Singer is Broker, NOMAD and corporate financial adviser on an ongoing basis;
• Dorsey & Whitney (Europe) LLP for general legal advice; and
• Menzies LLP for ongoing advice on VAT and PAYE.

Board Evaluation Process

The Board believes that, in addition to dealing with any matters as they arise, it is appropriate to carry out a formal evaluation of the performance of the Board each year. This is intended to ensure that the Board remains effective, well-informed and able to make high quality and timely decisions for the benefit of all stakeholders in the Company.

The first such evaluation was carried out in January 2019. This involved each Director completing an evaluation questionnaire which covers effectiveness from multiple angles including: Board structure and committees; Board arrangements, frequency and time; content of Board meetings; Board culture; Board evaluation and succession; and individual contributions. The completed questionnaires were anonymised and collated independently into a summary, and comments and any areas of concern were highlighted for discussion with the Board.

Area for consideration	Outcome
Board and committee structure and composition
The Board would benefit from having an NED with complementary skills, especially good contacts/knowledge of the Company’s target markets.	The Board decided to consider this further with a view to looking out for a potential NED with the right complementarity skills.
Currently the entire Board deals with Nomination matters and there is no Nomination Committee.	The Board feels this is currently appropriate for a company of this size. This will be kept under review, especially if there is a recruitment process to oversee.
Although one meeting a year is largely dedicated to strategy, the Board could spend more time discussing strategic matters at routine meetings.	The rolling agenda will be updated to allow for this, as well as giving more time to the review of R&D plans and outcomes.
A more formal process could be introduced for the evaluation of risks.	This will be implemented in 2019.

Succession planning

As is common with many small AIM listed companies, the Company does not have internal candidates to succeed existing Executive Directors. This will be kept under review, especially when recruiting for senior roles as vacancies arise. However, the Board does not believe it is appropriate to recruit additional Directors or senior personnel solely for the purpose of board succession planning.

Training of Directors 

It was recognised that there continues to be more regulation of which Directors need to be aware. The Board will continue to ensure that Directors receive appropriate support to keep up to date. The Chief Executive Officer has completed an Institute of Directors course in Company Direction.

Also, the Chief Executive Officer undertook one to one executive coaching and as part of that coaching anonymised feedback was taken from key stakeholders which in turn was discussed with the Chief Executive Officer.

The Company is committed to achieving the highest possible ethical standards in conducting its business. The Company expects all employees and Directors to maintain the same high standards. To achieve these ends, Microsaic encourages freedom of expression and speech.

Ethics is based on a set of principles and clear moral and ethical values. The Company takes its principles and values very seriously and when all else fails, expects staff at all levels to look to these principles and values for guidance.

Principles:

The Board has adopted the following four principless:

1. Management must lead by example. Good ethics should be most noticeable at the top. Every employee must be accountable to the same rules.
2. Corporate values must be implemented throughout the Company. Every forum and medium should be used to spread the message and, most of all, the Company must practice what it preaches.
3. Meetings with staff (both one on one and group) to discuss the values and what they mean to each employee must be undertaken when implementing a value system. This will help to get everyone in the Company on the same page and committed.
4. The values of the Company must endure changes in leadership. The longer ethical values last, the more ingrained they will become.

Values

The Company conducts its business around 7 core values:

1. Integrity – applying high ethical standards and being honest. The old adage, “honesty is the best policy” is true today more than ever. The Company will conduct its business with honesty to all stakeholders and will uphold high moral principles.
2. Mutual respect, empathy and trust in dealing with others. An environment of mutual respect, empathy and trust is necessary if a Company is to promote integrity. Trust in the workplace is critical to organizational success. You cannot optimize results by yourself; you need others’ support and assistance. Trust is something that must be gained over time. We are not “entitled” to others’ trust; we have to earn it. Respect is a term that defines the feeling of holding a company or person in high esteem.
3. Innovation – a passion to experiment and deliver new solutions. A focus on research and development is extremely important to the future success of the Company. The Company is looking to introduce new technologies, products, processes or upgrades that are designed to achieve both product differentiation and lower costs while at the same time delivering innovative solutions to meet customer needs.
4. Teamwork – drives high performance. As a small Company, Microsaic relies heavily on team work. No one person is bigger than the Company. A team approach is more efficient, faster, benefits from multi-skills especially in problem solving, increases learning opportunities and encourages a sense of belonging, which often translates to a greater sense of ownership and accountability for the work. The teams’ communication principles are to listen effectively and deliver; open, clear, complete, consistent and timely communication.
5. Quality – we take pride in everything we do. The Company is strongly focused on quality from the products it produces to the processes it operates. The Company has recently transitioned to ISO9001-2015. Focusing on the quality of our people, products and services will ultimately create a quality image for the Company.
6. Customer focus – go the extra mile for our customers. The Company assigns highest priority to customer satisfaction. We listen to our customers’ needs and create solutions for unmet customer needs.
7. Shareholder value – striving to deliver value to shareholders. The key objective of the Company is achieving sustainable profitability. Every employee should understand how he or she fits into the profitability picture. Everyone’s common goal should be to build a strong, profitable Company that will endure and provide reasonable returns to shareholders.

In 2019 the Board of Directors held 12 meetings including 9 face to face and 3 by conference call. The agenda for Board meetings is prepared by the Executive Directors (following an established framework) and agreed with the Chairman. In addition, a rolling agenda plan is in place with the aim of ensuring that the Board considers all the matters that it should, whilst allowing for the unexpected.  The rolling 12 month Board agenda plan is reviewed at least annually and updated as appropriate.

The Executive Directors prepare regular reports for each Board Meeting, typically this includes a: Chief Executive Officers Report, Health and Safety Report, Finance Report and other papers to support matters for consideration e.g. budget papers in November etc., which allow the Board to assess the Company’s activities and review its performance. The reports are submitted at least seven working days before the meeting. Non-Executive Directors are able to have discussions with other employees where they feel it is appropriate. Non-Executive Directors also have the authority (following discussions with the Chairman) to seek external independent advice as they think fit at the expense of the Company.

The attendance of the Directors at the regular Board Meetings and Committee Meetings during the year ended 31 December 2019 were as follows:

Name	Position	Regular Board Meetings	Finance & Audit Committee	Remuneration Committee
Peter Grant	Non-Executive Chairman	12 (12)	2 (2)	3 (3)
Glenn Tracey	Chief Executive Officer	12 (12)	n/a	n/a
Bevan Metcalf	Finance Director	12 (12)	n/a	n/a
Chris Buckley	Non-Executive Director	12 (12)	2 (2)	3 (3)
Andrew Holmes	Non-Executive Director1	5 (5)	1 (1)	2 (2)
Eric Yeatman	Non-Executive Director	12 (12)	1 (1)	3 (3)

¹ Resigned – 15 May 2019

Numbers in brackets denote the total number of meetings that each Director was eligible to attend during the year.

Conflict of Interest

The Directors must keep the Board advised of any interest that could potentially conflict with those of the Company. At any time when a Director believes that there may be a conflict, this should be disclosed to the Chairman and Chief Executive Officer without delay and at the start of the next Board meeting to the Board as a whole. Where a material conflict exists, the Director concerned must not participate in discussions or vote on that subject matter.

Finance & Audit Committee

The remit of the Finance & Audit Committee is documented in its terms of reference which have been adopted by the Board of Directors.

The purpose of the Committee is to assist the Board in the effective discharge of its responsibilities for corporate governance, financial reporting, corporate control and risk management. The Committee normally meets at least twice a year and, amongst other things, reviews the annual report and accounts with the external auditors and interim statements.

The Committee also approves external auditors’ fees and ensures auditors’ independence as well as focusing on compliance with legal requirements and accounting standards. The ultimate responsibility for reviewing and approving the annual financial statements and interim financial statements remains with the Board.

The members of the Finance & Audit Committee are: Chris Buckley, Eric Yeatman and Peter Grant. Mr Grant is the Chair of the Committee. The external auditors, Chief Executive Officer, Finance Director and other executives may be invited to attend Committee meetings at the discretion of the Committee.

The terms of reference can be found here.

Remuneration Committee

The remit of the Remuneration Committee is documented in its terms of reference which have been adopted by the Board of Directors.

The Remuneration Committee meets as required and at least twice a year. Its responsibilities include reviewing the performance of the Executive Directors, setting their remuneration levels, determining the payment of bonuses (if applicable) and other benefits and considering the grant of options under the Company share option schemes.

The members of the Remuneration Committee are: Eric Yeatman (Chair), Chris Buckley and Peter Grant.

The terms of reference can be found here.

Nomination Committee

At this stage, it is not considered appropriate for the Company to have a formally constituted Nominations Committee, however, this will be kept under review. Board appointments are considered by the Board as a whole.

Matters Reserved for the Board

The matters reserved for the Board are detailed below:

Responsibilities of the Board

The Board has approved the following list of areas and matters for which it has reserved responsibility (together with its committees).

Management structure and appointments

• Senior management responsibilities
• Board and other senior management appointments or removals
• Board senior management succession, training, development and appraisal
• Appointment or removal of Company Secretary
• Appointment or removal of internal auditor
• Remuneration, contracts, grants of options and incentive arrangements for senior management
• Delegation of the Board’s powers
• Agreeing membership terms of reference of Board committees and task forces
• Establishment of managerial authority limits for smaller transactions
• Matters referred to the Board by the Board committees.

Strategic / Policy considerations

• Business strategy
• Diversification/retrenchment policy
• Specific risk management policies including insurance, hedging, borrowing limits, treasury policy and corporate security
• Agreement of codes and ethics and business practices
• Receipt and Review of regular reports on internal controls
• Annual assessment of significant risks and effectiveness of internal controls
• Calling of shareholders’ meetings
• Avoidance of wrongful or fraudulent trading

Transactions

• Acquisitions and disposals of subsidiaries or other assets over £25,000
• Investment and other capital projects over £25,000
• Substantial commitments including:
• Pension funding
• Contracts in excess of one year’s duration
• Giving security over significant group assets (including mortgages and charges over the groups’ property)
• Contracts not in the ordinary course of business
• Actions or transactions where there may be doubt over propriety
• Approval of certain announcements, prospectuses, circulars and similar documents
• Disclosure of Directors’ interests
• Transactions with Directors or other related parties.

Finance

• Raising new capital and confirmation of major financing facilities
• Treasury policies including foreign currency and interest exposure
• Discussion of any proposed qualification to the accounts
• Final approval or annual and interim reports and accounts and accounting policies
• Appointment/proposal of auditors
• Charitable and political donations
• Approval and recommendations of dividends (currently not applicable)
• Approval of budgets for the year and periodic review during the year.

Internal controls

The Board is ultimately responsible for the Company’s system of internal control and for reviewing its effectiveness. This includes financial, operational and compliance controls and risk-management systems. Internal control systems are designed to meet the Company’s particular needs and the risks to which it is exposed. The internal control systems are designed to minimise rather than eliminate the risk of failure to achieve business objectives and by their nature can only provide reasonable and not absolute assurance against misstatement and loss.

General

• Governance of Company Pension Scheme
• Allotment, calls or forfeiture of shares
• Approval of Health and Safety policy
• Anti-Bribery policy.

 

PRINCIPLE TO BUILD TRUST

Remuneration Committee Report

This report is included in the Annual Report which can be found under Documents in the Investors section of the website.

Finance & Audit Commitee Report

This Report is included in the Annual Report.

Disclose voting at the AGM

The last AGM was held on 14 May 2019. All directors attended the AGM. All shareholders are invited to make use of the Company’s Annual General Meeting to raise any questions regarding the management or performance of the Company. The Notice of AGM is always printed in the back of the Annual Report.

All resolutions were passed by a show of hands at the 2019 AGM. The outcome of the proxy voting is as follows:

	Chairman of the meeting	Chairman of the meeting	Chairman’s
	FOR	AGAINST	Discretion	Abstain
	Votes	Votes	Votes	Votes
Ordinary Resolution 1	283,942,661	11,000	10,000	500
Ordinary Resolution 2	283,943,161	0	10,000	11,000
Ordinary Resolution 3	283,867,591	86400	10,000	170
Ordinary Resolution 4	283,867,591	86400	10,000	170
Ordinary Resolution 5	283,867,591	86400	10,000	170
Ordinary Resolution 6	283,954,161	0	10,000	0
Special Resolution 7	283,452,591	501,400	10,000	170
Special Resolution 8	283,463,591	490,400	10000	170
MAXIMUM VOTES WHICH MAY BE CAST 181,365,146
MAXIMUM VOTES WHICH MAY BE CAST 181,365,146

Interim Results and Annual Reports

These can be found on the Company’s website going back to 2010.

www.microsaic.com/investors/documents

Other Governance Related Material

Other materials such as AGM Notices, our 2011 Admission Document and Circulars when raising funds can also be found at:

www.microsaic.com/investors/documents